Skip to main content
Premium Trial:

Request an Annual Quote

Golden Helix to Provide Free Software Under New Initiative


NEW YORK (GenomeWeb) – Golden Helix said this week that it is launching a new initiative called Golden Helix Gives Back through which it will provide its software for free to academic researchers with limited funds.

The company is accepting applications from academic researchers using DNA-Seq, RNA-Seq, GWAS, or CNV methodologies, who are interested in getting an annual license to the company's SNP & Variation Suite (SVS) or its VarSeq product free of charge. SVS is an integrated collection of tools for managing, analyzing, and visualizing multifaceted genomic and phenotypic data. VarSeq software streamlines the process of annotating and filtering variants obtained from next generation sequencing pipelines.

Applications will be evaluated based on the importance of the biological question under study and the impact it may have on the field; the overall study design and analysis methodology; the research application and its benefits; financial need; and how Golden Helix software will assist in the research effort.

The initiative will open on November 10 and applicants have until December 5 this year to turn in their proposals. Golden Helix will award the top 3 applicants with annual licenses to either one of its two products. The winners will be announced on December 18.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.